Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRYZ | Q08257 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695627 | 0.78 | CRYZ (0.61) | CRYZKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL6697964 | 0.77 | CRYZ (0.65) | CRYZALDH1A1LMNAPOLBGAA | |
| SCHEMBL6693404 | 0.75 | CRYZ (1.00) | CRYZNPSR1KDM4EALOX15MAPK1 | |
| SCHEMBL974218 | 0.68 | MEN1 (0.36) | KDM4EALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL6691547 | 0.67 | CRYZ (1.00) | CRYZNPSR1KDM4EALOX15MAPK1 | |
| SCHEMBL6694531 | 0.65 | CRYZ (0.60) | CRYZNPSR1KDM4EALOX15MAPK1 | |
| SCHEMBL10556112 | 0.63 | EPHX1 (0.47) | ALDH1A1LMNAPOLBGAAMAPT | |
| SCHEMBL28373802 | 0.63 | SLC18A3 (0.45) | CRYZKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL10556119 | 0.63 | EPHX1 (0.47) | ALDH1A1LMNAPOLBGAAMAPT | |
| SCHEMBL10556132 | 0.63 | EPHX1 (0.47) | ALDH1A1LMNAPOLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | HU, LONGQIN | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | MKI67, NME2, NTPCR | CRYZ 1190/4885NPSR1 1115/4885KDM4E 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.